The Fort Collins Chamber will be closing at 4:00 pm, September 26 for our Business Tradeshow. The Chamber will reopen for regular hours on Friday, September 27. Click below for tickets & more info about the Tradeshow
Overview:FDA issued a guidance document covering GMP requirements for Phase 1 products.
These guidelines remove some of the problems that are encountered with early phase products and are in addition to those that cover the CMC sections for IND submissions at Phase 1.
Although the guidance appears to remove the need to follow GMPs for Phase 1 products, the need to follow GMPs is still present in the Food, Drug, and Cosmetic Act. Thus the nature and extent of GMP-related activities will depend upon the nature of the investigational drug and the extent of the study that is planned.
Areas Covered in the Session:
Discussion of the elements found in the guidance document for Phase 1 material
What to do at really early stages
What about special IND studies?
What about preclinical studies?
Varying GMP activities that depend upon the nature of the IND product
What are the requirements for the GMP found in the Food, Drug, and Cosmetic Act?
What to do about QC activities such as instrument qualification, method validation, and process validation
Who Will Benefit:
Regulatory Affairs Personnel who Coordinate Activities for the CMC Sections of Submissions
QA/QC Personnel who Need to Plan Work on Early Stage Material
R & D Personnel who Will Contribute data to CMC Sections
Project Managers for Product Development Studies
Quality Systems Auditors
Consultants
Speaker Profile
Steven S. Kuwahara , Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steven has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories . Steven has participated in the development of drugs and biologicals through all phases of clinical research and final product production.
Event link:
https://www.compliance4all.com/webinar/-502958LIVE?channel=fortcollinschamber_2020_SEO
Contact Info
Netzealous LLC, DBA -Compliance4all
Email: [email protected]
Phone: +1-800-447-9407
Website: https://www.compliance4all.com/